Dicks Sporting Goods Inc vs Moderna, Inc. — how do they compare? Dicks Sporting Goods Inc trades at $202.67 (market cap $18.35B), while Moderna, Inc. trades at $63.65 (market cap $24.18B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| DKS | MRNA | |
|---|---|---|
Market Cap | $18.35B | $24.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $81.80 |
52-Week Low | $187.78 | $22.36 |
Enterprise Value | $25.14B | $20.33B |
Dividend Yield | 2.44% | — |
Signals from Pluang's Aura AI — not financial advice
Dick's Sporting Goods (DKS) trades at $202.66, down 5.34% on the day, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a 4.71% net income margin and 20.9% ROE, while analyst consensus remains strongly bullish with a $263.22 price target. Recent news highlights DKS as a value stock pick with accelerating sales growth, though the stock faces near-term technical pressure.
The outlook remains positive given strong analyst support and consistent earnings performance, but investors should monitor the bearish technical indicators and upcoming Q2 2026 earnings report on August 25th. Key risks include retail sector competition and potential margin pressure as revenue growth outpaces profit growth in 2026 projections.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Trailing returns across standard periods
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →